The Identification of New Pharmacological Targets for the Treatment of Glaucoma: A Network Pharmacology Approach

<b>Background:</b> Glaucoma is a progressive optic neuropathy characterized by the neurodegeneration and death of retinal ganglion cells (RGCs), leading to blindness. Current glaucoma interventions reduce intraocular pressure but do not address retinal neurodegeneration. In this effort, to identify new pharmacological targets for glaucoma management, we employed a network pharmacology approach. <b>Methods:</b> We first retrieved transcriptomic data from GEO, an NCBI database, and carried out GEO2R (an interactive web tool aimed at comparing two or more groups of samples in a GEO dataset). The GEO2R statistical analysis aimed at identifying the top differentially expressed genes (DEGs) and used these as input of STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) app within Cytoscape software, which builds networks of proteins starting from input DEGs. Analyses of centrality metrics using Cytoscape were carried out to identify nodes (genes or proteins) involved in network stability. We also employed the web-server software MIRNET 2.0 to build miRNA-target interaction networks for a re-analysis of the GSE105269 dataset, which reports analyses of microRNA expressions. <b>Results:</b> The pharmacological targets, identified in silico through analyses of the centrality metrics carried out with Cytoscape, were rescored based on correlations with entries in the PubMed and clinicaltrials.gov databases. When there was no match (82 out of 135 identified central nodes, in 8 analyzed networks), targets were considered "potential innovative" targets for the treatment of glaucoma, after further validation studies. <b>Conclusions:</b> Several druggable targets, such as GPCRs (e.g., 5-hydroxytryptamine 5A (5-HT5A) and adenosine A<sub>2B</sub> receptors) and enzymes (e.g., lactate dehydrogenase A or monoamine oxidase B), were found to be rescored as "potential innovative" pharmacological targets for glaucoma treatment.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2024-10-05
DOI
https://doi.org/10.3390/ph17101333
Citations
2
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Identification of New Pharmacological Targets for the Treatment of Glaucoma: A Network Pharmacology Approach

Francesca Lazzara, Chiara Bianca Maria Platania, Claudio Bucolo, Federica Conti et al.
2 citations
Pharmaceuticals
Computational Drug Discovery Methods
0.72
article

The Identification of New Pharmacological Targets for the Treatment of Glaucoma: A Network Pharmacology Approach

Francesca Lazzara, Chiara Bianca Maria Platania, Claudio Bucolo, Federica Conti, Nicoletta Marcantonio, Filippo Drago, Erika Giuffrida
article en
2 citations

Abstract

<b>Background:</b> Glaucoma is a progressive optic neuropathy characterized by the neurodegeneration and death of retinal ganglion cells (RGCs), leading to blindness. Current glaucoma interventions reduce intraocular pressure but do not address retinal neurodegeneration. In this effort, to identify new pharmacological targets for glaucoma management, we employed a network pharmacology approach. <b>Methods:</b> We first retrieved transcriptomic data from GEO, an NCBI database, and carried out GEO2R (an interactive web tool aimed at comparing two or more groups of samples in a GEO dataset). The GEO2R statistical analysis aimed at identifying the top differentially expressed genes (DEGs) and used these as input of STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) app within Cytoscape software, which builds networks of proteins starting from input DEGs. Analyses of centrality metrics using Cytoscape were carried out to identify nodes (genes or proteins) involved in network stability. We also employed the web-server software MIRNET 2.0 to build miRNA-target interaction networks for a re-analysis of the GSE105269 dataset, which reports analyses of microRNA expressions. <b>Results:</b> The pharmacological targets, identified in silico through analyses of the centrality metrics carried out with Cytoscape, were rescored based on correlations with entries in the PubMed and clinicaltrials.gov databases. When there was no match (82 out of 135 identified central nodes, in 8 analyzed networks), targets were considered "potential innovative" targets for the treatment of glaucoma, after further validation studies. <b>Conclusions:</b> Several druggable targets, such as GPCRs (e.g., 5-hydroxytryptamine 5A (5-HT5A) and adenosine A<sub>2B</sub> receptors) and enzymes (e.g., lactate dehydrogenase A or monoamine oxidase B), were found to be rescored as "potential innovative" pharmacological targets for glaucoma treatment.

PharmaceuticalsVol. 17(10)
University of Catania (IT)
Good health and well-being
Openalex Percentile: Top 26%
Computational Drug Discovery Methods
0.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.